Shopping Cart 0
Cart Subtotal
USD 0

EMS SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Summary

EMS SA (EMS) is a pharmaceutical company, which is focused in the development of products for improvement of health and well-being of the population. It operates in prescription segments generics, branded pharmaceuticals, OTC and hospital. It has presence in the US market through Brace Pharma, a company focused on radical innovation. The company has production units in Sao Bernardo do Campo, in Jaguariuna and Hortolandia (SP), Novamed, located in Manaus (AM); and in Brasilia (DF). It exports to over 40 countries globally. EMS is headquartered in Hortolandia, Brazil.

EMS SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

EMS SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

EMS SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

EMS SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

EMS SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

EMS SA, Medical Devices Deals, 2012 to YTD 2018 9

EMS SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

EMS SA, Pharmaceuticals & Healthcare, Deal Details 14

Venture Financing 14

ReViral Raises USD55 Million in Series B Financing 14

Antiva Biosciences Raises USD15 Million in Series C-1 Financing 16

Precision BioSciences Raises USD110 Million in Venture Financing 18

Avrobio Raises USD60 Million in Series B Venture Financing 21

Antiva Biosciences Raises USD22 Million in Series C Financing 23

Avidity Biosciences Raises USD10 Million in Series B Venture Financing 24

F2G Raises USD60 Million in Venture Financing 26

Zymeworks Raises USD61.5 Million in Series A Financing 28

Navitor Pharma Raises USD33 Million in Series B Financing 30

miRagen Therapeutics Raises USD41 Million in Series C Financing 32

Therabron Therapeutics Raises USD6.75 Million in Second Tranche of Series B Financing Round 34

ReViral Raises USD21 Million in Series A Financing Round 35

Unum Therapeutics Raises USD65 Million in Series B Financing 36

Therabron Therapeutics Raises USD11 Million in Series B Venture Financing 38

Avidity NanoMedicines Raises USD6 Million in Series B Venture Financing 39

Tyrogenex Raises USD15 Million in Series D Venture Financing 40

Gliknik Raises Funds through Venture Financing 41

Licensing Agreements 42

Iroko Pharma Enters into Licensing Agreement with EMS for Zorvolex 42

BioAlliance Pharma Enters into Licensing Agreement with EMS for Sitavig 43

Equity Offering 44

miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 44

Acquisition 46

EMS to Acquire 93.7% Stake in Galenika for USD19 Million in Tender Offer 46

Government of Serbia to Sell Majority Stake in Galenika 47

Dermapharm Rumored To Acquire Galenika 48

Government of Serbia Plans To Sell 20% Stake In Galenika, Prescription Drug Manufacturer 49

EMS SA-Key Competitors 50

EMS SA-Key Employees 51

EMS SA-Locations And Subsidiaries 52

Head Office 52

Other Locations & Subsidiaries 52

Joint Venture 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54


List Of Figure

List of Figures

EMS SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

EMS SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

EMS SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

EMS SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

EMS SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

EMS SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

EMS SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

EMS SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

EMS SA, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

EMS SA, Pharmaceuticals & Healthcare, Key Facts 2

EMS SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

EMS SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

EMS SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

EMS SA, Deals By Therapy Area, 2012 to YTD 2018 8

EMS SA, Medical Devices Deals, 2012 to YTD 2018 9

EMS SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ReViral Raises USD55 Million in Series B Financing 14

Antiva Biosciences Raises USD15 Million in Series C-1 Financing 16

Precision BioSciences Raises USD110 Million in Venture Financing 18

Avrobio Raises USD60 Million in Series B Venture Financing 21

Antiva Biosciences Raises USD22 Million in Series C Financing 23

Avidity Biosciences Raises USD10 Million in Series B Venture Financing 24

F2G Raises USD60 Million in Venture Financing 26

Zymeworks Raises USD61.5 Million in Series A Financing 28

Navitor Pharma Raises USD33 Million in Series B Financing 30

miRagen Therapeutics Raises USD41 Million in Series C Financing 32

Therabron Therapeutics Raises USD6.75 Million in Second Tranche of Series B Financing Round 34

ReViral Raises USD21 Million in Series A Financing Round 35

Unum Therapeutics Raises USD65 Million in Series B Financing 36

Therabron Therapeutics Raises USD11 Million in Series B Venture Financing 38

Avidity NanoMedicines Raises USD6 Million in Series B Venture Financing 39

Tyrogenex Raises USD15 Million in Series D Venture Financing 40

Gliknik Raises Funds through Venture Financing 41

Iroko Pharma Enters into Licensing Agreement with EMS for Zorvolex 42

BioAlliance Pharma Enters into Licensing Agreement with EMS for Sitavig 43

miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 44

EMS to Acquire 93.7% Stake in Galenika for USD19 Million in Tender Offer 46

Government of Serbia to Sell Majority Stake in Galenika 47

Dermapharm Rumored To Acquire Galenika 48

Government of Serbia Plans To Sell 20% Stake In Galenika, Prescription Drug Manufacturer 49

EMS SA, Key Competitors 50

EMS SA, Key Employees 51

EMS SA, Other Locations 52

EMS SA, Subsidiaries 52

EMS SA, Joint Venture 53

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com